Technology area: Biotechnology & Pharmaceuticals
1 pending office actions • 1 art units • 1 examiners • 0 of 1 (0%) have an AI response strategy ready
Reponex Pharmaceuticals A/S operates in the Biotechnology & Pharmaceuticals technology area with a targeted patenting strategy. The portfolio currently includes 1 pending office action located in 1 distinct art unit. This concentration suggests a narrow scope for the entity's current prosecution activity.
The prosecution is handled by 1 distinct examiner, LEE, WILLIAM Y, who is also the busiest examiner with 1 busiest examiner pending action. Because the entire pending docket is managed by one person, the prosecution path is very streamlined. This structure places high importance on the specific feedback and standards of this single examiner.
Practitioners should focus on the specific procedural and technical preferences of the assigned examiner. Because the entire pending portfolio is subject to a single individual's review, the strategy must be precisely calibrated to that examiner's standards. This high level of concentration simplifies docket management but increases the importance of each filing.
Difficulty is derived from the rejection statutes on the most recent pending office action. §101-driven and multi-statute cases are graded Hard; §112-only and obviousness-type double-patenting cases are graded Easy; everything else is Medium. "Unknown" means we have not yet parsed a statute for that office action.
| Bucket | Cases |
|---|---|
| §103 only | 1 (100%) |
How the docket's pending cases split across USPTO tech-center bands.
Manual office-action response work runs about 10 hours per case. The time-saved bands below show what IP Author's prosecution pipeline typically delivers — a conservative 20% on the low end, 35% in the middle, 50% on the high end.
| Examiner | Apps on this docket | Allow rate | Interview lift |
|---|---|---|---|
| LEE, WILLIAM Y | 1 | 48.0% | +34.1% |
Cases in front of an examiner whose interview lift is 10 percentage points or more — i.e. interviewed cases historically resolve more favorably than non-interviewed ones. The top 1 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 16960223 | COMPOSITIONS FOR ELIMINATING BACTERIAL PROMOTORS OF COLORECTAL CANCER BY INTRALUMINAL APPLICATION | LEE, WILLIAM Y | — |
| Art Unit | Apps |
|---|---|
| 1623 | 1 |
| App # | Title | Examiner | Art Unit | Statutes | Status | Due in | AI | Filed |
|---|---|---|---|---|---|---|---|---|
| 16960223 | COMPOSITIONS FOR ELIMINATING BACTERIAL PROMOTORS OF COLORECTAL CANCER BY INTRALUMINAL APPLICATION | LEE, WILLIAM Y | 1623 | §103 | Final Rejection | — | Pending | Jul 06, 2020 |
IP Author helps IP teams respond to office actions faster with AI-generated responses, examiner analytics, and prosecution intelligence.
Start Free TrialReponex Pharmaceuticals A/S has 1 pending office actions as of October 2026, spread across 1 art units and 1 examiners.
William Y Lee has the most, with 1 of Reponex Pharmaceuticals A/S's pending office actions.
Mostly Biotechnology & Pharmaceuticals (USPTO Tech Center 1600), based on where its pending office actions are examined.
